Recently, the award ceremony for the 2025 Eighth Greater Bay Area Biotechnology Innovation Top 50 (hereinafter referred to as: Top 50) was held in Shenzhen. In recent years, the scale and influence of the Top 50 selection have continued to expand. The participating enterprises of this session are not only from the Greater Bay Area but also distributed across various regions in China, including Beijing, Suzhou, Hangzhou, Jiaxing, and more.
In the increasingly prosperous and competitive biotechnology innovation track, Xbiome stands out with its cutting-edge basic research achievements in gut microbiota, as well as its continuous output of innovative products and commercial collaboration cases.Awarded the "Leading Enterprise" in the Top 50 of Biotechnology Innovation in the Guangdong-Hong Kong-Macao Greater Bay Area. This is the third consecutive year that Xbiome has won the highest award in the Top 50 series.
Building on Scientific Research, Scaling the Heights of Industry
Xbiome is a leading AI microbiome research and development company in China. Over the past year, Xbiome has achieved remarkable results in gut microbiome research, with findings frequently published in globally renowned academic journals. The company has built a leading-scaleXBIOME GUT BIOBANK (XGB) Gut Microbiota Bank, Three Star Strains Uncovered ——XA-1416, XA-511, and XA-2103, with scientifically evidenced mechanism research and excellent data performance, have successively obtained national invention patent authorization and quickly achieved commercialization.
Among them, the XA-1416 strain has won numerous national and industry awards; Chang Yijun’s ready-to-eat probiotics, which utilize the XA-1416, XA-2103, and XA-8187 strains, will be fully launched in July 2025 across Cha Yan Yue Se's offline stores and online e-commerce platforms, leading the new health tea concept of "making patented strains accessible to everyone."
In the FMT (Fecal Microbiota Transplantation) field, April 2025,National Science and Technology Major Project"Research on the Creation and Clinical Evaluation of an Integrated Traditional Chinese and Western Medicine Prevention System for Primary Liver Cancer" Receives Official Approval from China's National Health Commission. In the project, institutions such as the Chinese PLA General Hospital and Xbiome Co. Ltd. conduct exploratory research on the topic of using gut microbiota modulation (FMT) combined with traditional Chinese medicine to improve symptoms and reduce the risk of liver cancer.
Xbiome's AI algorithm provides precise matching for fecal microbiota transplantation donors and patients, finding the best match for each patient and user."Optimal Donor", to maximize the effectiveness of gut microbiota transplantation. In addition,Xbiome has an FMT production system that complies with GMP and cGMP standards.To provide high-quality, high-tech transplant products for hospitals and enrolled patients, helping to build a "Chinese solution" for chronic disease prevention and treatment.
AI+BT: Leading the Innovation and Transformation of Microecology
In recent years,The Integration of AI and BT Biotechnology, is leading a new revolution in life science technology, providing a new driving force for the development of multiple industries such as biomanufacturing, pharmaceuticals, and health. Thanks to the integration of AI and BT, a completely new research paradigm and industrial pathway have emerged in the field of human gut microbiota.
In February 2025, the "Guangdong Provincial AI+BT Microbiome Engineering Technology Research Center" organized by Xbiome was officially recognized as the "2024 Annual Guangdong Provincial Engineering Technology Research Center."The evaluation criteria for provincial engineering centers are strict. Participating companies must demonstrate their strength and achievements in scientific research, as well as showcase outstanding capabilities in technological innovation, achievement transformation, and industrial application. Xbiome's standout performance reflects the high recognition of the company’s intestinal microbiology research and innovation capabilities.
Subsequently, with Xbiome as the理事长 unit,Guangdong-Hong Kong-Macao Greater Bay Area AI+BT Microecological Health Industry AllianceOfficially established, the alliance adheres to the concept of "collaborative technology research, resource sharing, and industrial prosperity," aiming to create a globally leading AI+BT micro-ecological health industry innovation consortium. Member organizations look forward to working with industry peers to leverage the power of AI+BT in driving innovation in the micro-ecological health industry, providing disease intervention and health management solutions that cover the entire life cycle for the public and consumers.
The alliance has pioneered the concept of gut microbiota microecology + cellular microecology within the industry."Dual-Ecosystem Therapy"——Breaking the limitations of a single perspective in traditional medicine, the human body is regarded as a complex ecosystem, emphasizing the impact of interactions between microbial communities and cellular environments on health, and opening up a new path for disease prevention and health management.
-End-